Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Negative Pressure Wound Therapy Market is Hotly Contested

This article was originally published in Start Up

Executive Summary

Negative pressure wound therapy is the largest single market ever seen in the wound care industry, worth more than $1 billion in 2008, according to "US Markets for Current and Emerging Wound Closurel Technologies," a report recently published by Medtech Insight. So, it's not surprising that companies are fighting battles here, in which no holds are barred.

You may also be interested in...

Smith & Nephew Challenges KCI in Wound Care

KCI created a wound healing market potentially worth $6 billion as the first company to offer a new modality known as negative pressure wound therapy. Having uncovered such a large potential market, it's only natural that it would attract competition, and it has. In March 2009, wound care leader Smith & Nephew launched its own negative pressure wound therapy product line. KCI isn't going to give up market share without a fight; it's talking up its advantages and defending its IP portfolio mightily.

KCI: In Wound Care, A Surfaces Company Goes Deep

Kinetic Concepts' 28-year overnight success story rests on an opportunistic acquisition designed to complement its core business in specialty beds designed to prevent or relieve wounds caused by patient immobility. In 1994, KCI acquired rights to the VAC (Vacuum Assisted Closure) Therapy System, a non-invasive wound closure device that uses controlled, localized negative pressure to help promote healing in chronic and acute wounds. VAC is now the company's principal growth driver, accounting for 71% of the company's revenues, and a growth rate of 28%. VAC has been everything that KCI hoped--and much more. But now, in order to penetrate the $3.3 billion markets that it is targeting, the company will have to move beyond the core hospital markets where it's been successful, to the more challenging extended care and home health care markets.

Wound Solutions Ltd.

Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts